FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589751944> ?p ?o ?g. }

• W2589751944 endingPage "695" @default.
• W2589751944 startingPage "683" @default.
• W2589751944 abstract "Talimogene laherparepvec is a first-in-class intralesional oncolytic immunotherapy. In a recent Phase III trial (OPTiM), talimogene laherparepvec significantly improved durable response rate compared with subcutaneous granulocyte–macrophage colony-stimulating factor (GM-CSF). Overall response rate was also higher in the talimogene laherparepvec arm, and the greatest efficacy was demonstrated in patients with earlier-stage (IIIB, IIIC, or IVM1a) melanoma. Talimogene laherparepvec was well tolerated, with the majority (89%) of adverse events being grade 1 or 2. Preclinical studies have shown that talimogene laherparepvec exerts antitumor activity by selectively replicating within and destroying cancer cells, and through the release of tumor-associated antigens and expression of GM-CSF, which facilitates a wider antitumor immune response. It is hypothesized that combining talimogene laherparepvec with a systemic immunotherapy may, by bringing together complementary mechanisms of action, further enhance the efficacy of both agents. Indeed, talimogene laherparepvec is currently being assessed in combination with immune checkpoint inhibitors, including ipilimumab and pembrolizumab, in trials for melanoma and other solid tumors. Early results in melanoma indicate that the combination of talimogene laherparepvec with ipilimumab or pembrolizumab has greater efficacy than either therapy alone, without additional safety concerns above those expected for each monotherapy. In this review, we discuss the latest results from trials assessing talimogene laherparepvec in combination with other immunotherapies, provide an overview of ongoing and upcoming combination trials, and suggest future directions for talimogene laherparepvec in combination therapy for solid tumors." @default.
• W2589751944 created "2017-03-03" @default.
• W2589751944 creator A5009968141 @default.
• W2589751944 creator A5030396965 @default.
• W2589751944 creator A5037399273 @default.
• W2589751944 creator A5089297467 @default.
• W2589751944 date "2017-02-25" @default.
• W2589751944 modified "2023-09-25" @default.
• W2589751944 title "Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors" @default.
• W2589751944 cites W1885611760 @default.
• W2589751944 cites W1898887656 @default.
• W2589751944 cites W1969357150 @default.
• W2589751944 cites W1970368422 @default.
• W2589751944 cites W1977362391 @default.
• W2589751944 cites W1987119981 @default.
• W2589751944 cites W1987328311 @default.
• W2589751944 cites W1988985184 @default.
• W2589751944 cites W1994993231 @default.
• W2589751944 cites W2001015151 @default.
• W2589751944 cites W2001062813 @default.
• W2589751944 cites W2006521968 @default.
• W2589751944 cites W2019034425 @default.
• W2589751944 cites W2060826949 @default.
• W2589751944 cites W2066671159 @default.
• W2589751944 cites W2082150850 @default.
• W2589751944 cites W2086591619 @default.
• W2589751944 cites W2097995306 @default.
• W2589751944 cites W2099648846 @default.
• W2589751944 cites W2100228832 @default.
• W2589751944 cites W2100991326 @default.
• W2589751944 cites W2109274792 @default.
• W2589751944 cites W2113544323 @default.
• W2589751944 cites W2113950128 @default.
• W2589751944 cites W2133075384 @default.
• W2589751944 cites W2134216634 @default.
• W2589751944 cites W2135885240 @default.
• W2589751944 cites W2145350167 @default.
• W2589751944 cites W2148377255 @default.
• W2589751944 cites W2152897456 @default.
• W2589751944 cites W2154813177 @default.
• W2589751944 cites W2163157738 @default.
• W2589751944 cites W2165320653 @default.
• W2589751944 cites W2166662937 @default.
• W2589751944 cites W2167521488 @default.
• W2589751944 cites W2170739773 @default.
• W2589751944 cites W2207677213 @default.
• W2589751944 cites W2215070146 @default.
• W2589751944 cites W2227073990 @default.
• W2589751944 cites W2272044596 @default.
• W2589751944 cites W2286391085 @default.
• W2589751944 cites W2341748465 @default.
• W2589751944 cites W2417489976 @default.
• W2589751944 cites W2417912780 @default.
• W2589751944 cites W2427476638 @default.
• W2589751944 cites W2463781662 @default.
• W2589751944 cites W2473956396 @default.
• W2589751944 cites W2560367415 @default.
• W2589751944 cites W2561986773 @default.
• W2589751944 cites W2572174216 @default.
• W2589751944 cites W2588209419 @default.
• W2589751944 cites W2599516047 @default.
• W2589751944 cites W2602107020 @default.
• W2589751944 cites W2682116888 @default.
• W2589751944 cites W2891708681 @default.
• W2589751944 cites W3190341154 @default.
• W2589751944 doi "https://doi.org/10.1007/s00262-017-1967-1" @default.
• W2589751944 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5445176" @default.
• W2589751944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28238174" @default.
• W2589751944 hasPublicationYear "2017" @default.
• W2589751944 type Work @default.
• W2589751944 sameAs 2589751944 @default.
• W2589751944 citedByCount "46" @default.
• W2589751944 countsByYear W25897519442017 @default.
• W2589751944 countsByYear W25897519442018 @default.
• W2589751944 countsByYear W25897519442019 @default.
• W2589751944 countsByYear W25897519442020 @default.
• W2589751944 countsByYear W25897519442021 @default.
• W2589751944 countsByYear W25897519442022 @default.
• W2589751944 countsByYear W25897519442023 @default.
• W2589751944 crossrefType "journal-article" @default.
• W2589751944 hasAuthorship W2589751944A5009968141 @default.
• W2589751944 hasAuthorship W2589751944A5030396965 @default.
• W2589751944 hasAuthorship W2589751944A5037399273 @default.
• W2589751944 hasAuthorship W2589751944A5089297467 @default.
• W2589751944 hasBestOaLocation W25897519442 @default.
• W2589751944 hasConcept C121608353 @default.
• W2589751944 hasConcept C126322002 @default.
• W2589751944 hasConcept C143998085 @default.
• W2589751944 hasConcept C2777658100 @default.
• W2589751944 hasConcept C2777701055 @default.
• W2589751944 hasConcept C2780057760 @default.
• W2589751944 hasConcept C2781433595 @default.
• W2589751944 hasConcept C502942594 @default.
• W2589751944 hasConcept C71924100 @default.
• W2589751944 hasConcept C82210918 @default.
• W2589751944 hasConceptScore W2589751944C121608353 @default.
• W2589751944 hasConceptScore W2589751944C126322002 @default.
• W2589751944 hasConceptScore W2589751944C143998085 @default.

• next